Trump Selects Dr. Heidi Overton to Lead FDA, Pending Senate Confirmation

By Arizona Asians Staff

Washington, D.C. — August 19, 2026 — President Donald Trump has selected White House health policy adviser Dr. Heidi Overton to serve as commissioner of the U.S. Food and Drug Administration. Dr. Overton must be confirmed by the Senate before taking charge of the agency. Until then, Kyle Diamantas will continue serving as acting FDA commissioner.

Physician and White House Policy Adviser

Dr. Overton is a physician and deputy director of the White House Domestic Policy Council, where she has helped develop the administration’s healthcare policies. She is board-certified in public health and general preventive medicine. Her professional background includes surgical training at Johns Hopkins University, service as a White House fellow during Trump’s first administration and leadership positions at the America First Policy Institute. President Trump said Dr. Overton would work to accelerate medical innovation, improve access to treatments, lower prescription-drug costs and advance his administration’s “Make America Healthy Again” agenda.

Health and Human Services Secretary Robert F. Kennedy Jr. welcomed the selection, praising Dr. Overton’s judgment and policy experience.

Leadership Change at a Powerful Agency

The position became vacant after Dr. Marty Makary left the FDA in May. The agency’s official leadership records show that Makary served from March 2025 until May 13, 2026. The FDA regulates products that affect nearly every American household, including prescription and over-the-counter medicines, vaccines, medical devices, most foods, dietary supplements, cosmetics and tobacco products. Its commissioner can influence the speed of drug approvals, food-safety enforcement, vaccine policy, tobacco regulation and the oversight of emerging medical technologies.

Supporters view her as a trusted policy adviser who understands the administration’s health agenda. Critics are expected to examine whether her policy positions could influence the FDA’s scientific and regulatory decisions.

What the Nomination Means for Consumers

FDA leadership decisions can directly affect the medicines, medical devices and food products available to the public. The agency also inspects imported products, investigates safety concerns and issues recalls and public-health warnings.

For Arizona families, healthcare providers, pharmaceutical companies and food businesses, the confirmation process will offer an early indication of how Dr. Overton might approach medical innovation, product safety and consumer protection.

Dr. Overton does not become FDA commissioner simply through the president’s announcement. She must complete the Senate confirmation process before assuming permanent leadership of the agency.